Stephanie O Klopfer

3PUBLICATIONS
21CO-AUTHORS
PharmacogenomicsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.

|Dec 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Amy E Colson, Gordon E Crofoot, Peter J Ruane

|Mar 13, 2025
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.

Jürgen K Rockstroh, Roger Paredes, Pedro Cahn

Pageof 1

Frequent Collaborators

2 joint publications

Karen Eves

1 joint publications

Alexandra W Dretler

1 joint publications

Ronald G Nahass

1 joint publications

Shauna Applin